Jane Street Group LLC Purchases 6,254 Shares of PepGen Inc. (NASDAQ:PEPG)

Jane Street Group LLC grew its position in PepGen Inc. (NASDAQ:PEPG) by 29.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 27,748 shares of the company’s stock after acquiring an additional 6,254 shares during the period. Jane Street Group LLC owned 0.09% of PepGen worth $237,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the stock. Wellington Management Group LLP raised its position in PepGen by 76.9% in the 3rd quarter. Wellington Management Group LLP now owns 40,517 shares of the company’s stock worth $346,000 after purchasing an additional 17,618 shares during the last quarter. Janus Henderson Group PLC raised its position in PepGen by 331.2% in the 3rd quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock worth $20,012,000 after purchasing an additional 1,794,641 shares during the last quarter. Walleye Capital LLC bought a new position in PepGen in the 3rd quarter worth approximately $519,000. Suvretta Capital Management LLC raised its position in PepGen by 9.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock worth $14,201,000 after purchasing an additional 140,000 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new position in PepGen in the 3rd quarter worth approximately $95,000. Institutional investors own 58.01% of the company’s stock.

PepGen Stock Performance

PEPG opened at $2.97 on Friday. The company has a fifty day moving average price of $4.65 and a two-hundred day moving average price of $8.88. PepGen Inc. has a 52 week low of $2.90 and a 52 week high of $19.30. The firm has a market capitalization of $96.81 million, a PE ratio of -1.00 and a beta of 1.66.

Analysts Set New Price Targets

PEPG has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $26.00 price objective on shares of PepGen in a research report on Friday, November 8th. Bank of America cut shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price objective for the company. in a research report on Monday, December 16th. Finally, Wedbush lowered their target price on shares of PepGen from $19.00 to $12.00 and set an “outperform” rating for the company in a report on Friday, November 8th.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.